Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-11-01
2009-06-30
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S228800, C514S234500, C514S253010, C514S259100
Reexamination Certificate
active
07553815
ABSTRACT:
A method of chemoprevention of the onset of invasive breast cancer in a high risk patient comprises administering to the patient an effective amount of an EGFR tyrosine kinase inhibitor.
REFERENCES:
patent: 5770599 (1998-06-01), Gibson
patent: 0 566 266 (1993-10-01), None
patent: WO 96/30347 (1996-10-01), None
patent: 97 02266 (1997-01-01), None
patent: WO 2008/026150 (2005-03-01), None
van Agthoven et al. (Amer. J. Path. 1994; 144: 1238-1246).
Granziero et al. (Eur. J. Immunol. 1999, 29:1127-1138).
Byers, T. (CA Journal, vol. 49, No. 6, Nov./Dec. 1999).
Kelloff et al. (Cancer Epidemiology, Biomarkers & Prevention 1996; 5: 657-666).
Smaill et al. (J. Med. Chem. 1999; 42: 1803-1815).
Bruns et al. (Cancer Research 2000; 60: 2926-2935).
Fisher (CA Cancer J. Clin. 1999; 49: 159-177).
Levitt et al. (Investigational New Drugs 1999; 17: 213-226, published Aug. 1999).
Stanta et al. (Virchows Arch 1998; 432: 107-111).
Driscoll D et al: “Effect of epidermal growth factor receptor tyrosine kinase inhibitor PD183805 on vascular endothelial growth factor secretion from several tumor models.” Proceedings of the American Association for Cancer Research Annual, vol. 40, Mar. 1999, p. 121.
Baselga J (Reprint) et al.: “A pharmacokinetic/pharmacodynamic trial of ZD1839 (IRESSA(TM)), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with 5 selected tumor types (a phase I/II trial of continuous once-daily treatment).” Clinical Cancer Research, (Nov. 1999) vol. 5, Supp. 'S!, pp. 29-29.
Smaill J.B. et al.: “Tyrosine kinase inhibitors. 15. 4- (Phenylamino)quinazoline and 4- (phenylamino)pyrido'd!pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.” Journal of Medicinal Chemistry, (May 20, 1999) 42/10 (1803-1815).
Ciardiello, Fortunato et al.: “Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD—1839 (Iressa), and epidermal growth factor receptor-selective tyrosine kinase inhibitor” Clin. Cancer Res. (2000), 6(5), 2053-2063.
Woodburn J.R.: “The epidermal growth factor receptor and its inhibition in cancer therapy.” Pharmacology and Therapeutics, (1999) 82/2 (241-250) , XP000965337 p. 241, col. 1, paragraph 1 p. 246, col. 1, paragraph 2.
McKinnon C.: “Prostate cancer, biological therapy, signal transduction inhibitors and anti-angiogenesis agents.” IDrugs (1999) 2/7 (624-628). , XP001015291 p. 626, col. 2, paragraph 4.
McKinnon C.: “Epidermal growth factor receptor targeting.” IDrugs. (1999) 2/7 (633-635). , XP001015294 p. 633, col. 1, paragraph 5 -col. 2, paragraph 3.
Bridges A.J.: “Current progress towards the development of tyrosine kinase inhibitors as anticancer agents.” Emerging Drugs, (1998) 3/- (279-292). , XP001015295 p. 282, paragraph 3 p. 281, paragraph 3.
C. Lu, et al. al, “Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors”, Journal of the National Cancer Institute, vol. 95, No. 24, Dec. 17, 2003, pp. 1825-1833.
M. Gail, et al., “Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually”, Journal of the National Cancer Institute, vol. 81, No. 24, Dec. 20, 1989, pp. 1879-1886.
G. Boland, “Biological Response to Hormonal Manipulation in Oestrogen Receptor Positive Ductal Carcinoma in situ of the Breast”, British Journal of Cancer, vol. 89, 2003, pp. 277-283.
J. Paez, et al., “EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy”, Science, vol. 304, Jun. 4, 2004, pp. 1497-1500.
G. Minckwitz, et al., “A Multicentre Phase II Study on Gefitinib in Taxane- and Anthraceycline-pretreated Metastatic Breast Cancer”, Breast Cancer Research and Treatment, vol. 89, 2005, pp. 165-172.
J. Soh, et al., “Impact of HER2 and EGFR gene status on Gefitinib-treated Patients wit Nonsmall-cell Lung Cancer”, Int. J. Cancer, vol. 121, 2007, pp. 1162-1167.
T. Pugh, et al., “Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients”, BMC Cancer 2007, 7:128.
B. Shoker, et al., “Estrogen Receptor-Positive Proliferating Cells in the Normal and Precancerous Breast”, American Journal of Pathology, vol. 155, No. 6, Dec. 1999.
A. Gandhi, et al, “Effects of a Pure Antiestrogen on Apoptosis and Proliferation within Human Breast Ductal Carcinoma in situ1”, Cancer Research 60, 4284-4288, Aug. 1, 2000.
N. Anderson, et al., “ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyroskine inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbb2 overexpression”, Int. J. Cancer: 94, 774-782 (2001).
V. Rusch, et al., “Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung”, Cancer Research 53, 2379-2385, May 15, 1993.
K. Chan, et al., Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. British Journal of Surgery 2001, 88, 412-418.
K. Chan, et al., Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Research 62, 122-128, Jan. 1, 2002.
W. Gulick, A new model for ductal carcinoma in situ suggests strategies for treatment. Breast Cancer Research. vol. 4 No. 5.
A. Tan, et al., Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. Journal of Clinical Oncology. vol. 22, No. 15. Aug. 1, 200.
C. Kari, et al., Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage1. Cancer Research 63: 1-5, Jan. 1, 2003.
N. Barnes, et al., Absence of HER4 Expression Predicts Recurrent of Ductal Carcinoma In Situ of the Breast. Clinical Cancer Research. vol. 11, 2163-2168, Mar. 15, 2005.
K. Robertson, et al., Quantitative Estimation of Epidermal Growth Factor Receptor and c-erbB-2 in Human Breast Cancer1. Cancer Research 56, 3823-3830, Aug. 15, 1996.
C. Fabian, et al., Prevalence of aneuploidy, overexpressed ER, and overexpressed EGFR in random breast aspirates of women at high and low risk for breast cancer. Breast Cancer Research and Treatment 30: 263-274, 1994.
Pilichowska et al. (1997) “Immunohistochemical Study of TGF-α, TGF-β1, EGFR, and IGF-1 Expression in Human Breast Carcinoma” Mod Pathol 10(10):969-975.
Mourad et al. (1997) “Predictors of Invasion in Ductal Carcinoma in Situ of the Breast: the Value of a Scoring System” Annals of Saudi Medicine 17(4):427-431.
Fetterolf Brandon J
Swanson & Bratschun L.L.C.
The University of Manchester
LandOfFree
Therapeutic use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4104033